EN

Translate:

  • HOME
  • BIO
  • SERVICES
  • REPRESENTATIVE MATTERS
  • EVENTS & NEWS
  • TALKS & ARTICLES
  • BLOG
  • CONTACT US
  • More
    • HOME
    • BIO
    • SERVICES
    • REPRESENTATIVE MATTERS
    • EVENTS & NEWS
    • TALKS & ARTICLES
    • BLOG
    • CONTACT US

EN

  • HOME
  • BIO
  • SERVICES
  • REPRESENTATIVE MATTERS
  • EVENTS & NEWS
  • TALKS & ARTICLES
  • BLOG
  • CONTACT US

Services -- Transactions Involving FDA-Regulated Products

FDA Regulatory Strategy and Freedom-to-Operate ("FTO") Validation (for Investments and Financings)

   ♦ Ensuring correct regulatory pathways
   ♦ Product line extensions
   ♦ Franchise protection (non-patent)
   ♦ Overcoming regulatory obstacles (e.g., Hatch-Waxman Exclusivity; approval criteria)
   ♦ FDA regulatory process impact on FTO 


Due Diligence Review

   ♦ Assessing FDA-related strengths and weaknesses of targeted companies/products
   ♦ FDA compliance issues presented by target transactional parties
   ♦ FDA approval status assessments 


Contract Drafting -- Comprehensive and Specific Clauses

   ♦ Product development and FDA-related milestones

   ♦ Indemnification – regulatory compliance

   ♦ Regulatory-related covenants, warranties & representations

For articles and presentations on transactions involving FDA-regulated products and companies, ...

click here
return to main services page

Copyright © 2017 - 2021.  Michael A. Swit - All Rights Reserved.   ♦   Site Terms (click to access)


Cookie Policy

This website uses cookies. By continuing to use this site, you accept our use of cookies.

Accept & Close